Danaher Corporation (DHR) SEC Filings & Earnings Calls

Respiratory revenue headwind of ~150bps in Q4 2026; core revenue growth impacted by declining COVID-related demand

“We expect respiratory revenue to be an approximately 150 basis point headwind, resulting in core revenue growth of approximately 3.0%.” · word for word

Integration risk from Masimo acquisition

“The acquisition of Masimo has provided, and is expected to provide, additional sales and earnings opportunities for the Company by expanding product line diversity, including new product offerings supporting acute care settings.” · word for word

China healthcare policy headwind

“Price decreases in the segment of 1.0% and 1.5%, respectively, in the three and nine-month periods ended September 25, 2026 were primarily attributable to the impact of China’s volume-based procurement program and reimbursement changes, as well as the impact of sales promotions and are reflected as a component of core sales above.” · word for word

Foreign exchange volatility

“The Company recorded foreign currency translation losses of $596 million and gains of approximately $2.4 billion for the nine-month periods ended September 25, 2026 and September 26, 2025, respectively.” · word for word

Leadership transition risk; new CEO compensation includes significant long-term incentives.

“CEO change with $20M special award; transition period through March 2027.”

Customer project timing impacted bioprocessing revenue, indicating potential lumpiness.

“While customer project timing impacted bioprocessing revenue, underlying order trends remained strong.” · word for word

Foreign currency estimated to decrease Q3 sales by 1.0%.

“Estimated impact of foreign currency on sales, which is estimated to decrease sales by 1.0% in the third quarter.” · word for word

China pricing pressure

“Price decreases in the segment of 1.5% in both the three and six-month periods ended June 26, 2026, primarily attributable to the volume-based procurement program in China and the impact of sales promotions in the six-month period ended June 26, 2026, negatively impacted the year-over-year change in sales” · word for word

Respiratory testing volatility

“The decreased demand for respiratory tests was driven primarily by a less severe respiratory season in the first half of 2026 compared to the comparable period of 2025.” · word for word

Integration risk from Masimo Acquisition

“Second quarter 2026 fair value adjustments to inventory, transaction costs deemed significant and pre-acquisition share-based and change-in-control payments, in each case related to the Masimo Acquisition in the Diagnostics segment - 175 basis points” · word for word

Foreign exchange volatility

“The Company recorded foreign currency translation losses of $149 million and gains of approximately $1.0 billion for the three-month periods ended June 26, 2026 and June 27, 2025, respectively.” · word for word

Increased leverage from new debt issuance, though terms are favorable with low fixed rates.

“CHF 2.38B notes with fixed rates 1.65%-2.51% across maturities 2031-2056.”

Potential shareholder dilution from increased equity compensation pool.

“20M share increase in Omnibus Incentive Plan.”

Special mandatory redemption if Masimo acquisition not completed by Nov 2026, requiring repayment at 101%.

“If Masimo Acquisition not consummated by Nov 16, 2026, Danaher must redeem Fixed Rate Notes at 101%.”

Lighter-than-typical Q1 respiratory season impacted Cepheid performance.

“Impact of a lighter-than-typical Q1 respiratory season at Cepheid.” · word for word

China VBP Pricing Pressure

“Price decreases in the segment of 2.0%, attributable to the volume-based procurement program in China and the impact of sales promotions, negatively impacted the year-over-year change in sales during the three-month period ended March 27, 2026 and are reflected as a component of core sales above.” · word for word

Tariff Cost Impact

“Year-over-year gross profit margin decreased during the three-month period ended March 27, 2026 as compared to the comparable period in 2025 primarily due to product mix, the impact of currency exchange rates and tariff costs, partially offset by the impact of continued productivity improvement initiatives and higher year-over-year sales volumes.” · word for word

Respiratory Seasonality Risk

“The relative severity of the upcoming respiratory season and the timing of customer purchases in the first quarter of 2026 in preparation of such respiratory season could adversely impact demand for such tests over the remainder of 2026.” · word for word

Leverage covenant of 0.65x; facility is unsecured with standard covenants.

“Consolidated Leverage Ratio of 0.65 to 1.00 or less required.”

Pledge of Shares by Founders

“Certain shares of Common Stock owned by Steven Rales and by Mitchell Rales were exempted from the policy because such shares had been pledged for decades, to secure lines of credit that reduce the need to sell shares for liquidity purposes.” · word for word

Cybersecurity Risk

“We also strive to implement and maintain layered controls designed to prevent and, where necessary, detect and respond to cybersecurity threats, including controls designed to facilitate identification of third-party cybersecurity risks.” · word for word

Macroeconomic and Regulatory Challenges

“During 2025, Danaher operated in a dynamic environment marked by significant policy and regulatory shifts across geographies and continued macro-economic challenges for the healthcare industry.” · word for word

Acquisition Integration Risk

“The Masimo transaction is subject to customary closing conditions, including receipt of applicable regulatory clearances and Masimo shareholder approval.” · word for word

Talent Retention and Competition

“The science and technology markets in which we operate are competitive, with demand sometimes exceeding the supply of talent, which has resulted in significant increases in compensation paid by many of the companies with whom we compete for talent.” · word for word

Tariff escalation risk

“If delayed or additional tariffs are implemented, the Company would incur additional tariff costs that could be material and the Company’s revenue and profitability could be adversely impacted.” · word for word

China healthcare policy headwind

“Price decreases in the segment of 1.0%, primarily attributable to the volume-based procurement program and healthcare reimbursement changes in China and to a lesser extent, sales promotions, negatively impacted the year-over-year change in sales during 2025” · word for word

Life Sciences research funding pressure

“Lower funding levels at emerging biotechnology customers and in the academic and government end-markets reduced demand for the segment’s products during the period.” · word for word

Goodwill impairment risk

“The reporting unit with an excess of the estimated fair value over carrying value of 20% (and 10% under the sensitivity test) had a carrying value of approximately $10.1 billion.” · word for word

Transaction subject to regulatory approvals; antitrust and foreign investment reviews may delay or block deal.

“Consummation subject to HSR Act waiting period and certain non-U.S. antitrust and foreign direct investment approvals.”

Forward-looking statements subject to risks including tariffs, global economy, and competition.

“Forward-looking statements” · word for word

Board composition change may signal governance transition, but no operational impact indicated.

“Retirement not due to disagreement; board size reduction from 13 to 12.”